Epizyme, Inc
EPZM
EPZM was delisted on the 11th of August, 2022.
67 hedge funds and large institutions have $566M invested in Epizyme, Inc in 2013 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 21 increasing their positions, 11 reducing their positions, and 8 closing their positions.
225% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 8
91% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 11
51% more capital invested
Capital invested by funds: $374M → $566M (+$192M)
37% more funds holding
Funds holding: 49 → 67 (+18)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$11.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.42M |
| 3 |
SCM
Sigma Capital Management
Stamford,
Connecticut
|
+$4.4M |
| 4 |
QBFM
QS Batterymarch Financial Management
New York
|
+$4.28M |
| 5 |
RFC
Russell Frank Company
Seattle,
Washington
|
+$3.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$4.77M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$4.32M |
| 3 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$2.83M |
| 4 |
ICAP
Independence Capital Asset Partners
Denver,
Colorado
|
-$2.34M |
| 5 |
Morgan Stanley
New York
|
-$2.11M |
EPZM Hedge Fund Activity: Q3 2013 in Review
67 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q3 2013, worth a combined $566M — up 51% from $374M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new EPZM positions and 8 closed out — a net gain of 18 holders — while 21 added to existing stakes and 11 trimmed.
The largest buyer was Driehaus Capital Management, adding an estimated $11.6M. The largest seller was RA Capital Management, cutting an estimated $4.77M.
- 67 institutional investors held Epizyme, Inc (EPZM) as of Q3 2013, up from 49 in Q2 2013.
- Funds reported $566M of Epizyme, Inc stock for Q3 2013, up 51% quarter-over-quarter.
- 26 funds opened new Epizyme, Inc positions in Q3 2013 and 8 closed out, a net change of +18 holders.
- The largest Epizyme, Inc buyer in Q3 2013 was Driehaus Capital Management, an estimated $11.6M added.
- The largest Epizyme, Inc seller in Q3 2013 was RA Capital Management, an estimated $4.77M sold.
Based on aggregated 13F filings for Q3 2013.